Israel
-
Tel Aviv Sourasky Medical Center launches first global clinical trial of Silexion’s KRAS-targeting therapy for pancreatic cancer
The clinical trial will assess SIL204, an investigational treatment developed by Silexion using small interfering RNA (siRNA) technology.
-
Sheba Medical Center collaborates with OpenAI to increase access to healthcare AI models
Under the agreement, Sheba physicians will receive early access to new healthcare models before their wider release, while the partnership will also expand research collaboration between the two organizations.
-
Evogene collaborates with Blavatnik Center to advance Israeli biotech ecosystem
Under the agreement, researchers will gain access to an integrated platform that combines Evogene’s AI-powered computational chemistry engine, ChemPass AI, with the BCDD’s laboratory infrastructure and drug discovery expertise.
-
Schneider Children’s Medical Center administers world’s first WWOX gene therapy for rare epilepsy
The therapy builds on long-standing research led by Prof. Rami Aqeilan of the Hebrew University of Jerusalem, who helped uncover the critical role of the WWOX gene in brain development.
-
Teva announces 250 layoffs at Israel plant after failed sale
The move comes as Teva advances plans to divest its API unit, Teva Active Pharmaceutical Ingredients (TAPI), a process first announced in January 2024.
-
Scinai acquires Recipharm’s Israeli API facility in strategic CDMO partnership
Scinai will retain the plant’s entire workforce as it integrates the facility into its CDMO operations.